Novlead registers post-market study of INOwill N200 nitric oxide device for neonatal PPHN
Trial NCT07837921 will evaluate the portable iNO delivery system in newborns with hypoxic respiratory failure and pulmonary hypertension.
Novlead's only listed clinical activity this week is a newly registered post-market study of its nitric oxide delivery device.
- The trial, NCT07837921, is a prospective, multicenter, single-arm, post-market clinical study evaluating the performance, safety, usability, and medico-economic aspects of the INOwill-N200 device when used to deliver inhaled nitric oxide to neonates requiring iNO therapy as part of their clinical care.1 It is sponsored by Novlead Inc., with Medi-Link as a collaborator, and plans to enroll 50 participants.1 The study is not yet recruiting, with an estimated start of October 2026 and estimated primary completion in April 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.